Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 17/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1009515 | 0.87 | KMT2A (0.52) | FAAHKMT2A | |
| SCHEMBL2543044 | 0.82 | CYP3A4 (0.55) | FAAHCYP2C9CYP3A4CYP2D6 | |
| SCHEMBL1011440 | 0.81 | FAAH (0.48) | FAAHCYP2C9CYP3A4CYP2D6 | |
| SCHEMBL1011526 | 0.81 | FAAH (0.62) | FAAHCYP2C9CYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL1011522 | 0.80 | FAAH (0.61) | FAAHCYP2C9CYP3A4CYP2D6 | |
| SCHEMBL1011759 | 0.79 | CYP3A4 (0.52) | FAAHCYP2C9CYP3A4CYP2D6 | |
| SCHEMBL1011080 | 0.77 | FAAH (0.47) | FAAHCYP2C9 | |
| SCHEMBL1014138 | 0.77 | THRB (0.49) | FAAHCYP2C9 | |
| Hydrochloric Acid SCHEMBL1010179 | 0.76 | MAPK1 (0.56) | FAAHCYP3A4CYP2D6HPGD | |
| SCHEMBL1009363 | 0.75 | FAAH (0.49) | FAAHCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8044052-B2 | Inhibitors of fatty acid amide hydrolase; N-pyridin-3-yl-4-(3-{[5-(trifluoromethyl)pyridin-2-yl]oxy}benzylidene)piperidine-1-carboxamide; elevate brain anandamide levels; pain, urinary incontinence, cognitive disorders, anxiety, depression, sleeping, eating, movement disorders, glaucoma, psoriasis | PFIZER INC. (US) | 2011-10-25 | — | — | US | disclosed |
| EP-2076508-B1 | BIARYL ETHER UREA COMPOUNDS | PFIZER PROD INC (US) | 2011-01-05 | — | — | EP | disclosed |
| EP-2076508-A2 | BIARYL ETHER UREA COMPOUNDS | Pfizer Products Inc. (US) | 2009-07-08 | — | — | EP | disclosed |
| US-20080261941-A1 | Biaryl Ether Urea Compounds | Jazz Pharmaceuticals Therapeutics, Inc. | 2008-10-23 | — | — | US | disclosed |
| WO-2008047229-A2 | BIARYL ETHER UREA COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2008-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261941-A1 | Biaryl Ether Urea Compounds | FAAH, FAAH2, LIPC | FAAH 1/4885CYP2C9 136/4885CYP3A4 303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.